Liver steatosis commonly known as fatty liver is no longer a silent bystander in liver health. It’s the central feature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition that’s quietly becoming a major global health burden.

What was once dismissed as benign fat accumulation in the liver is now understood to be the starting point of a progressive liver disease spectrum from steatosis to inflammation, fibrosis, and potentially cirrhosis or cancer.

­

Why Liver Steatosis Deserves More Attention

The European Association for the Study of the Liver (EASL) recently emphasized that MASLD is closely linked to rising rates of obesity, type 2 diabetes, insulin resistance, and metabolic syndrome. But what makes steatosis especially concerning is how common and undetected it remains. You can have significant fat buildup in your liver without any symptoms. By the time conventional tests raise flags, damage may already be progressing.

­

Who’s Most at Risk?

Emerging research highlights that sex, body mass index, and diabetes status all influence how likely someone is to develop or progress with liver steatosis. This reinforces the need for wider screening, especially in metabolic clinics and primary care settings.

­

Diagnostic Challenges

Despite being widespread, liver steatosis often goes undiagnosed. Here’s why:

• Liver biopsy is invasive, risky, and expensive – not suitable for large-scale screening.

• Ultrasound, though commonly used, lacks sensitivity for detecting early-stage steatosis.

• CT scans expose patients to radiation and miss mild fat accumulation.

• Advanced imaging (like MRI or VCTE) shows promise, but adoption is limited due to cost and access barriers.

These limitations mean that many high-risk patients especially those with diabetes, high BMI, or PCOS remain undiagnosed until later stages of MASLD.

­

LIVERFASt: A New Era in Liver Diagnostics

With all the diagnostic challenges, that’s where LIVERFASt comes in. It is a breakthrough blood-based diagnostic tool that quantifies steatosis, fibrosis, and inflammation (NASH activity) all in a single test.

With just a simple blood draw, healthcare providers can now:

• Detect steatosis before symptoms begin

• Monitor changes in liver fat over time

• Guide personalized lifestyle and treatment interventions

As MASLD becomes more widespread, solutions like LIVERFASt will be key to catching liver disease early, acting faster, and protecting lives.